Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.33 |
| ▸ | FABP7 | O15540 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | MDM4 | O15151 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278711 | 1.00 | KMT2A (0.35) | KMT2ACASP1MDM2FABP5FABP7 | |
| SCHEMBL22092037 | 0.86 | KMT2A (0.39) | KMT2AMDM2FABP5FABP7EPHX2 | |
| SCHEMBL30278742 | 0.85 | KMT2A (0.47) | KMT2AMDM2FABP5FABP7EPHX2 | |
| SCHEMBL22091999 | 0.85 | KMT2A (0.47) | KMT2AMDM2FABP5FABP7EPHX2 | |
| SCHEMBL12314878 | 0.84 | KMT2A (0.41) | KMT2ACASP1FABP5FABP7EPHX2 | |
| SCHEMBL7062622 | 0.83 | KMT2A (0.42) | KMT2AMDM2FABP5FABP7EPHX2 | |
| SCHEMBL29516484 | 0.83 | KMT2A (0.42) | KMT2AMDM2FABP5FABP7EPHX2 | |
| SCHEMBL25657528 | 0.83 | KMT2A (0.39) | KMT2AMDM2FABP5FABP7EPHX2 | |
| SCHEMBL25657526 | 0.81 | KMT2A (0.40) | KMT2ACASP1MDM2FABP5FABP7 | |
| SCHEMBL31000664 | 0.81 | KMT2A (0.36) | KMT2AFABP5FABP7EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-3896056-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | VIP, DNPEP, HM13 | KMT2A 3453/4885CASP1 3474/4885MDM2 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.